Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 2) (Cth)

Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 2)1

Statutory Rules 2001 No. 802

I, WILLIAM PATRICK DEANE, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973.

Dated 19 April 2001

WILLIAM DEANE

Governor-General

By His Excellency’s Command

MICHAEL WOOLDRIDGE

Minister for Health and Aged Care

1Name of Regulations

 These Regulations are the Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 2).

2Commencement

 These Regulations commence on 1 May 2001.

3Amendment of Health Insurance (Pathology Services Table) Regulations 2000

Schedule 1 amends the Health Insurance (Pathology Services Table) Regulations 2000.

Schedule 1Amendments

(regulation 3)

  

[1]Schedule 1, Part 2, subrule 4 (1)

omit

item 66500 or 66584,

insert

item 66500, 66503, 66506, 66509, 66512, 66515 or 66584

[2]Schedule 1, Part 2, after rule 23

insert

24Antineutrophil cytoplasmic antibody tests

 For subsection 16A (3) of the Act, a request for

an antineutrophil cytoplasmic antibody immunofluorescence test is taken to include a request for an antineutrophil proteinase 3 antibody test and an antimyeloperoxidase antibody test if:

• (a)

  the immunofluorescence test performed as a result of the request is abnormal; or

• (b)

  a previous immunofluorescence test was abnormal; or

• (c)

  those antibodies have been previously detected.

[3]Schedule 1, Part 3, new items 66655, 71153, 71155, 71157, 71159

insert each of the following items in its correct numerical position

66655	Prostate specific antigen (PSA) quantitation in the assessment of clinically suspected prostatic disease — 1 patient episode in a 12 month period	19.90
71153	Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody by 1 of the following tests: (a) antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test; (b) antineutrophil proteinase 3 antibody (PR3 ANCA) test; (c) antimyeloperoxidase antibody (MPO ANCA) test; (d) antiglomerular basement membrane antibody (GBM ANCA) test (See rule 24)	34.10
71155	Testing for the presence of 2 antibodies by tests mentioned in item 71153 (See rule 24)	46.80
71157	Testing for the presence of 3 antibodies by tests mentioned in item 71153 (See rule 24)	59.50
71159	Testing for the presence of 4 antibodies by tests mentioned in item 71153 (See rule 24)	72.20

[4]Schedule 1, Part 3, item 66656

substitute

66656 Prostate specific antigen (PSA), quantitation in the monitoring of previously diagnosed prostatic disease — each patient episode to a maximum of 4 tests (including a test to which item 66655 applies) in a 12 month period 19.90

[5]Schedule 1, Part 3, item 66659

substitute

66659 Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index in the follow up of a PSA result that lies in the equivocal range of the particular method of assay used to determine the level — 1 test (including a test to which item 66656 applies) in a 12 month period 36.65

[6]Schedule 1, Part 3, item 71109

omit

glomerular basement membrane,

[7]Schedule 1, Part 3, item 71109

omit

neutrophil cytoplasm,

Notes

1. These Regulations amend Statutory Rules 2000 No. 293, as amended by 2001 No. 4.

2. Notified in the Commonwealth of Australia Gazette